144 related articles for article (PubMed ID: 10639032)
1. Synthesis, characterization, and imaging performance of a new class of macrocyclic hepatobiliary MR contrast agents.
Marinelli ER; Neubeck R; Song B; Wagler T; Ranganathan RS; Sukumaran K; Wedeking PW; Nunn A; Runge VM; Tweedle MF
Invest Radiol; 2000 Jan; 35(1):8-24. PubMed ID: 10639032
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
[TBL] [Abstract][Full Text] [Related]
3. Comparison of gadolinium Cy2DOTA, a new hepatobiliary agent, and gadolinium HP-DO3A, an extracellular agent, in healthy liver and metastatic disease.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1995 Feb; 30(2):123-30. PubMed ID: 7782188
[TBL] [Abstract][Full Text] [Related]
4. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881
[TBL] [Abstract][Full Text] [Related]
5. Detectability of small liver metastases with gadolinium BOPTA.
Runge VM; Lee C; Williams NM
Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
[TBL] [Abstract][Full Text] [Related]
6. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA.
Runge VM
J Comput Assist Tomogr; 1998; 22(4):643-50. PubMed ID: 9676461
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of standard and high-dose contrast-enhanced breath-hold liver magnetic resonance for visualization of metastatic disease in an animal model.
Runge VM
Invest Radiol; 1998 May; 33(5):263-7. PubMed ID: 9609484
[TBL] [Abstract][Full Text] [Related]
8. Contrast-enhanced magnetic resonance imaging in a spinal epidural tumor model.
Runge VM; Lee C; Iten AL; Williams NM
Invest Radiol; 1997 Oct; 32(10):589-95. PubMed ID: 9342117
[TBL] [Abstract][Full Text] [Related]
9. Gadolinium-phthalein complexone as a contrast agent for hepatobiliary MR imaging.
Kawamura Y; Endo K; Koizumi M; Watanabe Y; Saga T; Konishi J; Horiuchi K; Yokoyama A
J Comput Assist Tomogr; 1989; 13(1):67-70. PubMed ID: 2910950
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: an animal study.
Hsu JS; Jaw TS; Liu GC; Wang YM; Chen SH; Kuo YT; Jao JC; Li CW; Tsai KB
J Magn Reson Imaging; 2004 Oct; 20(4):632-9. PubMed ID: 15390149
[TBL] [Abstract][Full Text] [Related]
11. Choice of metal ion and formulation concentration for first-pass brain perfusion studies with magnetic resonance imaging at 1.5 tesla.
Runge VM; Wells JW
Invest Radiol; 1996 Jul; 31(7):395-400. PubMed ID: 8818779
[TBL] [Abstract][Full Text] [Related]
12. Gadolinium Complex of 1,4,7,10-Tetraazacyclododecane-1,4,7-trisacetic Acid (DO3A)-Ethoxybenzyl (EOB) Conjugate as a New Macrocyclic Hepatobiliary MRI Contrast Agent.
Baek AR; Kim HK; Park S; Lee GH; Kang HJ; Jung JC; Park JS; Ryeom HK; Kim TJ; Chang Y
J Med Chem; 2017 Jun; 60(12):4861-4868. PubMed ID: 28530407
[TBL] [Abstract][Full Text] [Related]
13. Early dynamic magnetic resonance imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Aug; 31(8):472-8. PubMed ID: 8854193
[TBL] [Abstract][Full Text] [Related]
14. Renal metastasis. Detection and characterization on enhanced magnetic resonance imaging using an animal model.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1997 Apr; 32(4):212-7. PubMed ID: 9101356
[TBL] [Abstract][Full Text] [Related]
15. High-dose applications of gadolinium chelates in magnetic resonance imaging.
Runge VM; Kirsch JE; Thomas GS
Magn Reson Med; 1991 Dec; 22(2):358-63. PubMed ID: 1812371
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, characterization, and relaxation studies of Gd-DO3A conjugate of chlorambucil as a potential theranostic agent.
Kaur J; Tsvetkova Y; Arroub K; Sahnoun S; Kiessling F; Mathur S
Chem Biol Drug Des; 2017 Feb; 89(2):269-276. PubMed ID: 28205399
[TBL] [Abstract][Full Text] [Related]
17. Gd-DISIDA--a potential contrast agent for magnetic resonance imaging of the hepatobiliary system.
Saha GB; Bateson BP; Meaney TF; Ng TC; Go RT; MacIntyre WJ; Feiglin DH; O'Donnell JK
J Nucl Med Allied Sci; 1989; 33(1):1-6. PubMed ID: 2746364
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system.
Schuhmann-Giampieri G; Schmitt-Willich H; Press WR; Negishi C; Weinmann HJ; Speck U
Radiology; 1992 Apr; 183(1):59-64. PubMed ID: 1549695
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging.
Chong HS; Garmestani K; Bryant LH; Milenic DE; Overstreet T; Birch N; Le T; Brady ED; Brechbiel MW
J Med Chem; 2006 Mar; 49(6):2055-62. PubMed ID: 16539394
[TBL] [Abstract][Full Text] [Related]
20. An intravascular MRI contrast agent based on Gd(DO3A-Lys) for tumor angiography.
Yang CT; Chandrasekharan P; He T; Poh Z; Raju A; Chuang KH; Robins EG
Biomaterials; 2014 Jan; 35(1):327-36. PubMed ID: 24138829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
